Crossmark

The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study

Crossref DOI link: https://doi.org/10.1186/s13046-021-02056-9

Published Online: 2021-09-06

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sciuto, Rosa

Rea, Sandra

Ungania, Sara

Testa, Antonella

Dini, Valentina

Tabocchini, Maria Antonella

Patrono, Clarice

Soriani, Antonella

Palma, Valentina

Marconi, Raffaella

Strigari, Lidia http://orcid.org/0000-0003-4293-2298
License Information

Text and Data Mining valid from 2021-09-06

Version of Record valid from 2021-09-06
More Information

Article History

Received: 19 April 2021

Accepted: 31 July 2021

First Online: 6 September 2021

Declarations

:

: The pilot study has been approved from the Ethics Committee of Regina Elena National Cancer Institute (N:RS1083/18–2111).

: Not applicable.

: All the authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below